Rapid Microbiology Testing Market Size, Share, Growth, and Industry Analysis, By Type (Growth-Based, Viability-Based, Cellular Component-Based, Nucleic Acid-Based, Other), By Application (Diagnostic Laboratories & Hospitals, Pharmaceutical & Biotechnology Companies, Food & Beverage Companies, Contract Research Organizations, Other), Regional Insights and Forecast to 2035

The Rapid Microbiology Testing Market

The global Rapid Microbiology Testing market size was valued at USD 6312.06 million in 2026 and is projected to grow from USD 13474.74 million in 2026 to USD 13474.74 billion by 2035, exhibiting a CAGR of 8.8% during the forecast period.

The Rapid Microbiology Testing Market is expanding due to increasing contamination monitoring across pharmaceutical manufacturing, biologics production, food processing, and hospital diagnostics. More than 72% of pharmaceutical facilities adopted automated microbial detection platforms in 2025, compared to 51% in 2020. Around 64% of biologics manufacturers now use nucleic acid-based rapid microbiology testing systems for sterility validation. Rapid Microbiology Testing Market Analysis indicates that over 48% of laboratory workflows are now partially automated with AI-assisted microbial interpretation tools. More than 39 countries implemented stricter microbial contamination standards between 2022 and 2025, increasing deployment of rapid testing instruments by 33% across regulated industries.

The United States remains a leading market for rapid microbiology testing due to its advanced pharmaceutical manufacturing, biotechnology expansion, and stringent quality control requirements. The country hosts more than 5,000 FDA-registered drug manufacturing facilities and thousands of clinical laboratories adopting molecular diagnostics and automated microbial detection systems. Growing production of biologics, cell therapies, and sterile injectables has accelerated demand for rapid sterility and contamination testing. U.S. hospitals and life science companies increasingly implement PCR-, ATP bioluminescence-, and MALDI-TOF-based technologies to shorten testing times from several days to hours, improving patient management, manufacturing efficiency, and regulatory compliance.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: More than 74% of pharmaceutical manufacturers increased rapid sterility testing adoption, while 68% of biologics facilities shifted toward automated contamination monitoring and 57% of diagnostic laboratories implemented same-day microbial detection platforms during 2024 and 2025.
• Major Market Restraint: Approximately 43% of small laboratories reported high implementation costs, 39% experienced integration difficulties with legacy systems, and 34% faced shortages of trained microbiologists capable of operating advanced rapid microbiology testing instruments.
• Emerging Trends: Nearly 62% of laboratories adopted AI-supported microbial identification, 58% integrated cloud-connected analyzers, and 46% increased utilization of nucleic acid amplification technologies for faster pathogen confirmation within less than 6 hours.
• Regional Leadership: North America represented nearly 38% of rapid microbiology testing demand, Europe contributed 29%, Asia-Pacific accounted for 24%, and Middle East & Africa captured approximately 9% of overall industry-wide testing implementation activity.
• Competitive Landscape: The top 5 manufacturers controlled nearly 54% of total instrument deployment, while automated microbial identification platforms represented 61% of competitive product launches and 49% of companies expanded laboratory automation partnerships during 2025.
• Market Segmentation: Growth-based testing held nearly 32% share, nucleic acid-based testing accounted for 29%, pharmaceutical applications represented 34%, and diagnostic laboratories contributed approximately 28% of total Rapid Microbiology Testing Market Size worldwide.
• Recent Development: During 2023-2025, more than 41% of leading companies launched automated microbial analyzers, 36% introduced AI-based pathogen detection software, and 28% expanded regional manufacturing capacity for rapid microbiology testing consumables.

Rapid Microbiology Testing Market Latest Trends

The Rapid Microbiology Testing Market Trends indicate significant transformation through automation, molecular diagnostics, and digital laboratory integration. Approximately 66% of pharmaceutical quality control laboratories adopted automated microbial detection technologies in 2025. Rapid Microbiology Testing Market Research Report findings show that test turnaround time decreased from 5 days to less than 24 hours in 58% of regulated facilities using automated systems. Nucleic acid amplification technologies represented nearly 29% of all new product installations due to accuracy levels exceeding 95% in pathogen identification workflows.

Cloud-based laboratory information management systems increased integration rates by 44% between 2022 and 2025. Around 52% of food and beverage manufacturers implemented rapid contamination testing to reduce batch rejection rates. AI-assisted microbial identification tools improved sample interpretation efficiency by 37% across clinical laboratories. More than 49% of biotechnology companies integrated real-time environmental monitoring systems with rapid microbiology testing platforms. Portable microbial analyzers gained strong demand, especially in decentralized healthcare settings, with adoption increasing by 31% in emerging markets. Rapid Microbiology Testing Market Outlook data shows that automated endotoxin testing usage expanded by 42% in injectable pharmaceutical production facilities. Single-use testing cartridges represented nearly 47% of consumables demand due to reduced contamination risk and lower manual handling requirements.

Rapid Microbiology Testing Market Dynamics

DRIVER

"Rising demand for pharmaceuticals and biologics"

The expansion of pharmaceutical manufacturing and biologics production is a major driver in the Rapid Microbiology Testing Market Growth trajectory. Global biologics manufacturing capacity increased by 28% between 2021 and 2025, directly increasing sterility testing requirements. More than 71% of injectable drug manufacturers implemented rapid microbial testing to comply with contamination standards. Hospitals reported a 26% increase in bloodstream infection monitoring programs, creating higher demand for rapid pathogen identification technologies. Rapid Microbiology Testing Market Insights reveal that 63% of vaccine manufacturers adopted automated sterility testing systems to reduce batch release timelines from 14 days to under 7 days. Continuous manufacturing facilities increased rapid microbial monitoring utilization by 34%, particularly in North America and Europe. Pharmaceutical outsourcing also accelerated testing demand, with 46% of contract manufacturers expanding microbiology laboratories between 2023 and 2025.

RESTRAINT

"High setup and validation complexity"

Despite technological progress, the Rapid Microbiology Testing Market faces restraints linked to validation costs and technical complexity. Approximately 41% of small and medium-sized laboratories reported delays in implementation due to regulatory validation requirements. Automated microbial testing systems require calibration accuracy exceeding 98%, increasing operational complexity for laboratories with limited technical staff. Nearly 38% of healthcare facilities continue relying on conventional culture-based testing due to compatibility issues with digital laboratory infrastructure. Training costs increased by 23% in advanced microbiology laboratories after adoption of AI-assisted platforms. More than 33% of food processing facilities reported difficulties integrating rapid testing systems into existing HACCP frameworks. Regulatory differences across 27 countries also create compliance challenges for multinational testing providers. Instrument maintenance intervals averaging every 6 months contribute to operational downtime concerns in high-throughput environments.

OPPORTUNIT

"Expansion of personalized medicines and cell therapies"

Rapid growth in personalized medicine, gene therapy, and cell therapy production is creating significant opportunities for the Rapid Microbiology Testing Market Opportunities segment. Cell therapy clinical trials increased by 36% globally during 2024 and 2025, requiring rapid sterility validation before patient administration. Approximately 59% of advanced therapy medicinal product manufacturers integrated rapid nucleic acid-based microbial detection systems into production workflows. Hospital-based cell therapy laboratories expanded contamination monitoring capacity by 31% in 2025. Portable rapid testing devices gained adoption in decentralized biopharmaceutical manufacturing units, where turnaround times below 8 hours are critical. More than 47% of precision medicine developers invested in automated microbial screening technologies for small-volume production environments. Asia-Pacific biotechnology clusters expanded cleanroom microbiology testing capacity by 29%, creating strong demand for consumables, reagents, and automated analyzers.

CHALLENGE

"Rising costs and shortage of skilled professional"

The Rapid Microbiology Testing Industry Analysis identifies skilled workforce shortages and operating expenses as key challenges. Nearly 44% of microbiology laboratories reported difficulty recruiting trained specialists capable of handling molecular diagnostic platforms. Advanced testing systems require continuous operator certification, increasing annual training hours by 21%. Laboratory automation software upgrades increased operational expenditures for 37% of pharmaceutical facilities. More than 32% of healthcare institutions experienced delays in system deployment due to cybersecurity integration requirements for connected laboratory instruments. Environmental monitoring regulations became stricter across 22 major pharmaceutical manufacturing countries between 2023 and 2025, increasing compliance workloads. Rapid technology evolution also shortened product replacement cycles to approximately 4 years in high-throughput laboratories, pressuring capital budgets and procurement planning.

Segmentation Analysis

The Rapid Microbiology Testing Market is segmented by type and application, with nucleic acid-based and growth-based technologies accounting for nearly 61% of total installations. Pharmaceutical and biotechnology companies represent the largest application segment with approximately 34% share due to increasing sterility validation requirements. Diagnostic laboratories account for 28% of testing demand as hospital-acquired infection surveillance expands globally. Food and beverage applications contribute around 19% because contamination prevention regulations intensified across packaged food manufacturing facilities. Rapid Microbiology Testing Market Forecast data indicates that automated molecular technologies continue replacing conventional culture methods in more than 52% of newly established microbiology laboratories worldwide.

Download FREE Sample to learn more about this report.

By Type

Growth-Based: Growth-based rapid microbiology testing systems accounted for approximately 32% of global deployment in 2025. These systems are widely used in pharmaceutical sterility testing because microbial growth detection sensitivity exceeds 94% in controlled laboratory conditions. More than 67% of injectable drug manufacturing facilities utilize automated growth-based analyzers for contamination screening. Detection time has decreased from 7 days to less than 48 hours in modern growth-based platforms. Around 43% of vaccine production laboratories implemented continuous incubation monitoring technologies between 2023 and 2025.

Viability-Based: Viability-based testing technologies represented nearly 18% of the Rapid Microbiology Testing Market Share in 2025. These methods use ATP bioluminescence and fluorescence-based analysis to identify living microorganisms within minutes. Approximately 54% of food safety laboratories integrated viability-based rapid testing systems into routine contamination monitoring workflows. Pharmaceutical cleanroom monitoring applications increased by 29% due to demand for faster environmental testing. Viability-based assays reduced manual sample handling by 41% in automated laboratories. More than 38% of cosmetic manufacturing facilities adopted viability-based microbial screening technologies for preservative effectiveness testing.

Cellular Component-Based: Cellular component-based technologies captured around 12% share of the Rapid Microbiology Testing Industry Report landscape. These methods analyze microbial proteins, enzymes, and membrane structures for rapid identification. Approximately 46% of hospital laboratories using MALDI-TOF systems integrated cellular component analysis into pathogen identification workflows. Identification times decreased from 48 hours to under 2 hours in advanced clinical laboratories. Around 31% of blood culture testing facilities adopted cellular component-based microbial identification systems. Pharmaceutical contamination investigations utilizing protein fingerprinting technologies increased by 24% between 2023 and 2025.

Nucleic Acid-Based: Nucleic acid-based testing accounted for approximately 29% of Rapid Microbiology Testing Market Size due to high sensitivity and low turnaround time. PCR-based and sequencing-based technologies are increasingly used in biologics production, hospital diagnostics, and food safety laboratories. More than 72% of biotechnology firms adopted nucleic acid-based microbial detection for contamination control. Pathogen identification accuracy exceeded 97% in multiplex PCR systems. Around 49% of pharmaceutical companies reduced sterility release timelines by integrating rapid nucleic acid amplification testing. Clinical laboratories processing more than 1,000 samples weekly increased molecular testing implementation by 35% during 2025.

Other: Other rapid microbiology testing technologies, including impedance microbiology and flow cytometry, represented nearly 9% of the market in 2025. Flow cytometry-based microbial analysis reduced sample processing times by 58% compared to conventional methods. Approximately 27% of research laboratories adopted impedance-based systems for water quality testing. Environmental monitoring programs in pharmaceutical facilities increased flow cytometry utilization by 21%. More than 18% of academic microbiology centers integrated hybrid testing systems combining AI analytics with automated microscopy. Advanced imaging-based microbial analyzers improved contamination detection precision by 26% in industrial laboratories.

By Application

Diagnostic Laboratories & Hospitals: Diagnostic laboratories and hospitals accounted for approximately 28% of the Rapid Microbiology Testing Market in 2025. Hospital-acquired infection monitoring programs expanded by 31% globally between 2022 and 2025. More than 62% of tertiary care hospitals implemented rapid pathogen detection systems to reduce patient diagnosis timelines below 6 hours. Automated blood culture testing systems improved sepsis detection efficiency by 43%. Around 54% of hospital microbiology laboratories adopted molecular microbial identification technologies. Emergency departments increased rapid infectious disease screening capacity by 29%, particularly in North America and Europe.

Pharmaceutical & Biotechnology Companies: Pharmaceutical and biotechnology companies held nearly 34% market share due to stringent sterility testing regulations. More than 76% of biologics manufacturing facilities conduct daily rapid microbial monitoring. Vaccine manufacturing plants increased automated endotoxin testing adoption by 39% between 2023 and 2025. Around 63% of injectable drug production facilities integrated real-time environmental monitoring systems. Continuous manufacturing lines reduced contamination response times by 44% using automated rapid microbiology platforms. The Rapid Microbiology Testing Market Analysis shows that outsourced pharmaceutical testing laboratories expanded microbiology capacity by 28% globally.

Food & Beverage Companies: Food and beverage companies represented around 19% of market demand in 2025. Food contamination recalls increased microbial testing frequency by 27% across packaged food manufacturing facilities. Approximately 58% of dairy processors implemented rapid pathogen detection technologies for Salmonella and Listeria screening. Beverage manufacturers reduced microbial testing turnaround times by 46% using automated analyzers. Around 42% of meat processing facilities adopted ATP-based hygiene monitoring systems. Export-oriented food manufacturers increased nucleic acid-based contamination testing utilization by 33% to meet international compliance standards.

Contract Research Organizations: Contract research organizations accounted for approximately 11% of the Rapid Microbiology Testing Market Share. Outsourced pharmaceutical testing increased by 24% between 2022 and 2025, driving rapid microbial testing adoption among CROs. More than 49% of CRO laboratories implemented automated sterility testing systems for biologics and biosimilar development. Environmental monitoring services expanded by 28% across clinical trial manufacturing facilities. Around 36% of CROs integrated AI-based microbial identification software into routine workflows. Pharmaceutical clients increasingly demand contamination reporting within 24 hours, encouraging faster analytical infrastructure deployment.

Other: Other applications, including cosmetics, water treatment, and academic research, represented nearly 8% of total market demand. Cosmetic manufacturing facilities increased preservative efficacy testing frequency by 21% between 2023 and 2025. Water treatment laboratories adopted rapid microbial monitoring technologies at a rate of 26% annually. Academic research institutions expanded microbial genomics testing capacity by 18%. Environmental agencies introduced stricter microbial contamination thresholds in drinking water systems across 19 countries. Portable rapid testing systems gained strong demand in field-based environmental monitoring applications.

Regional Outlook

The Rapid Microbiology Testing Market demonstrates strong regional growth across North America, Europe, Asia-Pacific, and Middle East & Africa. North America holds nearly 38% market share due to advanced pharmaceutical manufacturing and hospital diagnostics. Europe accounts for 29% with strict microbial safety regulations, while Asia-Pacific captures 24% through expanding biotechnology production. Middle East & Africa contribute 9% with increasing healthcare infrastructure modernization and food safety testing adoption.

Download FREE Sample to learn more about this report.

North America

North America remained the leading region in the Rapid Microbiology Testing Market, accounting for nearly 38% of global demand in 2025. The region benefits from advanced pharmaceutical manufacturing infrastructure, strong healthcare spending, and widespread adoption of laboratory automation technologies. More than 6,200 pharmaceutical production facilities and over 4,500 hospital microbiology laboratories across the United States and Canada actively use rapid microbial detection systems for sterility testing, contamination monitoring, and pathogen identification. Approximately 69% of biotechnology companies in the United States integrated nucleic acid-based microbial testing platforms into quality assurance workflows, especially for biologics and injectable drug production.

Hospital-based infectious disease surveillance also contributed significantly to regional market expansion. More than 58% of hospitals across North America implemented automated sepsis detection and molecular diagnostic systems linked with rapid microbiology analyzers. Canada increased food safety microbial testing capacity by 22% between 2023 and 2025 due to stricter packaged food contamination regulations. AI-supported laboratory automation improved sample throughput by 37%, reducing testing turnaround time from several days to less than 24 hours in many facilities. Environmental monitoring compliance requirements increased rapid testing frequency by 28% in pharmaceutical cleanrooms.

Europe

Europe accounted for approximately 29% of the Rapid Microbiology Testing Market Size in 2025, supported by strict microbial safety regulations, advanced biologics manufacturing, and strong healthcare laboratory networks. Germany, France, Italy, and the United Kingdom collectively generated more than 61% of regional pharmaceutical microbial testing activities. Approximately 57% of biologics manufacturing facilities in Europe adopted automated environmental monitoring systems to improve contamination control and regulatory compliance. Pharmaceutical companies across the region increasingly implemented rapid sterility testing technologies to shorten batch release timelines and improve manufacturing efficiency. Hospital microbiology laboratories in Europe expanded molecular diagnostic implementation by 31% between 2022 and 2025.

Rapid pathogen identification systems became increasingly important for monitoring hospital-acquired infections and antibiotic-resistant microorganisms. Food safety regulations also strengthened across Europe, increasing microbial screening frequency by 26% among packaged food exporters and dairy manufacturers. Around 48% of pharmaceutical companies integrated AI-based microbial identification software into quality control laboratories to improve detection precision and reduce manual interpretation errors. Vaccine production facilities increased rapid endotoxin testing usage by 33%, especially for biologics and injectable formulations. Research collaborations between biotechnology companies and academic institutions expanded microbiology automation projects by 24%. Sustainability initiatives also encouraged adoption of low-waste consumables and reusable testing components in more than 40% of regional laboratories.

Asia-Pacific

Asia-Pacific represented nearly 24% of the Rapid Microbiology Testing Market Share in 2025 and emerged as the fastest growing manufacturing and healthcare region. China, India, Japan, and South Korea collectively accounted for more than 68% of regional pharmaceutical production and biologics manufacturing activities. The rapid expansion of pharmaceutical exports from China and India increased demand for sterility testing and contamination monitoring across more than 3,000 production facilities. Approximately 52% of biotechnology startups in Asia-Pacific adopted rapid microbial contamination testing technologies for biologics, biosimilars, and vaccine manufacturing applications.

Hospital diagnostic laboratories across the region increased molecular microbial testing utilization by 35% between 2023 and 2025 due to rising infectious disease surveillance programs. Japan expanded automated clinical microbiology testing capacity by 27% in tertiary healthcare institutions, while South Korea increased investment in AI-based laboratory automation systems. Food safety modernization programs across Southeast Asia increased rapid pathogen screening adoption by 29%, particularly in seafood, dairy, and packaged food manufacturing sectors. Governments throughout Asia-Pacific also increased laboratory infrastructure funding, resulting in 22% growth in automated microbiology installations. Portable analyzers and compact PCR systems gained popularity in decentralized healthcare environments and rural diagnostic centers.

Middle East & Africa

Middle East & Africa accounted for approximately 9% of the global Rapid Microbiology Testing Market in 2025, supported by expanding healthcare infrastructure, food safety modernization, and increasing pharmaceutical production. Gulf countries experienced strong growth in rapid microbial diagnostics due to healthcare transformation projects and rising hospital investments. Hospital infrastructure modernization programs increased rapid microbiology testing implementation by 24% across the region. Saudi Arabia and the United Arab Emirates together contributed nearly 46% of healthcare laboratory upgrades related to molecular diagnostics and contamination monitoring systems. Food import regulations strengthened significantly, increasing microbial contamination screening frequency by 19% across regional food processing and distribution facilities.

South Africa expanded hospital-based molecular diagnostics programs by 21% between 2023 and 2025, particularly for infectious disease surveillance and antimicrobial resistance monitoring. Approximately 37% of pharmaceutical manufacturing sites in the region adopted automated environmental monitoring technologies to improve cleanroom contamination control and regulatory compliance. Water treatment authorities also increased microbial testing requirements by 17% to strengthen public health monitoring systems and improve drinking water quality assessment. Biotechnology research activity in the Middle East increased laboratory automation demand by 14%, especially in vaccine manufacturing and biologics research projects.

Top key Rapid Microbiology Testing Players

• Abbott Laboratories
• BD
• Merck
• Bruker
• Danaher
• Thermo Fisher Scientific
• Biomerieux
• Charles River Laboratories
• Neogen
• TSI
• Quidel Corporation
• Vivione Biosciences

Investment Analysis and Opportunities

The Rapid Microbiology Testing Market Opportunities landscape is expanding rapidly due to increased investment in laboratory automation, biologics manufacturing, and advanced contamination monitoring systems. Pharmaceutical manufacturers increased spending on microbial quality assurance and contamination prevention technologies by 31% between 2022 and 2025. More than 48% of biotechnology investors prioritized automated sterility testing systems and molecular microbial diagnostics while upgrading production infrastructure. Venture capital funding directed toward rapid pathogen identification and AI-assisted microbiology platforms increased by 26% globally during the same period.

Approximately 37% of newly planned pharmaceutical manufacturing facilities incorporated AI-enabled microbiology laboratories and cloud-connected testing systems into their operational frameworks.  Government-backed healthcare modernization programs across more than 20 countries accelerated demand for rapid infectious disease testing solutions. Hospital laboratory infrastructure projects expanded molecular microbiology testing installations by 29% in emerging economies. Food safety agencies also increased microbial compliance monitoring budgets by 18%, encouraging food processing companies to adopt automated rapid testing technologies. Outsourced pharmaceutical testing organizations increased investment in microbiology automation by 24% to reduce batch release timelines and improve operational efficiency. Portable analyzers, cybersecurity-enabled cloud systems, AI-powered microbial identification software, and automated environmental monitoring solutions represent major investment areas.

New Product Development

New product development in the Rapid Microbiology Testing Market is strongly focused on automation, AI-driven microbial analysis, cloud integration, and rapid contamination monitoring capabilities. Between 2023 and 2025, more than 41% of newly introduced rapid microbiology systems included cloud-based laboratory data management and remote monitoring functionality. Multiplex PCR analyzers capable of simultaneously identifying over 20 microbial pathogens increased by 32% in global commercial launches. Portable microbial testing devices weighing less than 5 kilograms gained substantial demand in decentralized healthcare settings, emergency diagnostics, and mobile laboratory applications.

AI-powered microbial identification software significantly improved sample interpretation accuracy, with advanced hospital laboratories reporting accuracy levels above 96%. Automated environmental monitoring platforms reduced contamination response times by 39% in pharmaceutical cleanrooms and biologics production facilities. Approximately 44% of manufacturers launched touchscreen-enabled analyzers equipped with remote calibration and predictive maintenance features. Single-use reagent cartridges expanded by 28% because they minimize contamination risks and simplify laboratory workflows. Miniaturized rapid testing systems designed for point-of-care diagnostics increased by 23% globally, especially in emerging healthcare markets. Flow cytometry-based analyzers capable of processing more than 1,500 samples per day entered large pharmaceutical manufacturing facilities during 2025.

Five Recent Developments (2023-2025)

Report Coverage of Rapid Microbiology Testing Market

The Rapid Microbiology Testing Market Report delivers a comprehensive evaluation of technologies, applications, and regional developments influencing microbial detection across pharmaceutical, biotechnology, healthcare, and food safety industries. The report studies more than 120 companies operating in automated microbial testing systems, rapid sterility analyzers, nucleic acid-based diagnostics, and contamination monitoring platforms across over 40 countries. Approximately 65% of the analysis emphasizes automated and molecular testing technologies because laboratories increasingly require pathogen detection within less than 24 hours instead of conventional methods requiring 3 to 7 days. The report provides detailed segmentation covering growth-based, viability-based, cellular component-based, nucleic acid-based, and hybrid rapid microbiology testing technologies.

More than 75 quantitative indicators are examined, including laboratory automation rates, environmental monitoring frequency, hospital-acquired infection surveillance, cleanroom contamination levels, and pharmaceutical sterility validation practices. Regional evaluation includes North America, Europe, Asia-Pacific, and Middle East & Africa with detailed assessment of testing installations, regulatory compliance standards, and adoption percentages. Additionally, the Rapid Microbiology Testing Market Research Report reviews over 50 recent product launches and 35 strategic collaborations focused on AI-powered microbial identification, cloud-connected analyzers, portable diagnostic systems, and automated environmental monitoring technologies used in high-throughput laboratories and healthcare facilities.

• 2025: bioMérieux expanded pharmaceutical quality control capabilities by promoting advanced rapid microbial methods for faster sterility assurance and product release in regulated manufacturing environments.
• 2025: Rapid Micro Biosystems strengthened commercialization of its Growth Direct platform and secured additional financing to support manufacturing expansion and global deployment of automated microbial detection systems.
• 2024: Charles River Laboratories continued expanding rapid endotoxin and microbial quality testing solutions for biopharmaceutical manufacturers, supporting accelerated release testing workflows.
• 2024: Thermo Fisher Scientific enhanced its microbiology testing portfolio through investments in bioprocess and laboratory automation technologies aimed at reducing contamination risks in pharmaceutical production.
• 2023: Becton, Dickinson and Company (BD) advanced automated microbiology and diagnostic platforms supporting faster pathogen identification and antimicrobial susceptibility testing across U.S. healthcare laboratories.